Skip to main content

Clinical Trials Using Elacestrant

Review the clinical trials studying elacestrant on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-9 of 9

A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Status: Active
Location: 48 locations
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer
Status: Active
Location: 20 locations
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment
Status: Active
Location: 14 locations
Circulating Tumor DNA Guided Treatment with Elacestrant in Stage IIB or III Hormone Receptor Positive HER2 Negative Breast Cancer, CATE Trial
Status: Active
Location: 12 locations
Elacestrant with or Without Abemaciclib for the Treatment of p53 Wild Type, Estrogen Receptor Positive Advanced or Recurrent Endometrial Cancer, The ELITE Trial
Status: Active
Location: 7 locations
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Status: Active
Location: 6 locations
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Status: Active
Location: 4 locations
Elacestrant Alone Compared to Elacestrant plus a CDK4/6 Inhibitor (Palbociclib, Abemaciclib, or Ribociclib) for Treating Patients with an ESR1 Mutation and ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer
Status: Active
Location: Northwestern University, Chicago, Illinois
Phase 1/2 Study to Evaluate Vosilasarm (EP0062) as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Status: Active
Location: Massachusetts General Hospital Cancer Center, Boston, Massachusetts